NCT01148537View on ClinicalTrials.gov

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

132

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

December 31, 2004

Study Completion Date

December 31, 2004

Conditions

Healthy Volunteers

Interventions

DRUG

Buprenorphine transdermal patch

Buprenorphine transdermal patch 5, 10, 20, and 2 \* 20 mcg/h.

DRUG

Matching placebo transdermal patch

Placebo transdermal patch to match BTDS 5, 10, 20, and 2 \* 20.

DRUG

Avelox (moxifloxacin hydrochloride) tablet

Moxifloxacin 400 mg tablet; 1 tablet taken orally on days 6 and 13

Trial Locations (1)

78704

PPD Development, LP, Clinics, Austin

All Listed Sponsors

lead

Purdue Pharma LP

INDUSTRY

NCT01148537 - The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers | Biotech Hunter | Biotech Hunter